Ginkgo Bioworks Holdings, Inc. Files Notice of Proposed Sale of Restricted Securities with SEC

Strategic Insights -

Ginkgo Bioworks Holdings, Inc., a biotech company, has filed a Form 144 with the U.S. Securities and Exchange Commission (SEC), disclosing plans to sell restricted securities. The filing, which was made on August 14, 2023, indicates that the company intends to sell securities held by an affiliate in reliance on Rule 144, exceeding 500 shares or units with an aggregate sales price of $10,000. This filing is a routine process for publicly-traded companies and is subject to specific rules and regulations.

Key Takeaways:

  • Ginkgo Bioworks Holdings, Inc. has filed a Form 144 with the SEC, stating intention to sell restricted securities.
  • The filing, made on August 14, 2023, is related to the sale of securities held by an affiliate in reliance on Rule 144.
  • The proposed sale exceeds 500 shares or units and has an aggregate sales price in excess of $10,000.
  • Form 144 is a formal document or financial statement submitted to the SEC by publicly-traded companies, which is necessary when selling restricted securities.
  • Ginkgo Bioworks Holdings, Inc. has provided contact information for the company, including its address and phone number.

Statistics:

  • The proposed sale of restricted securities exceeds 500 shares or units.
  • The aggregate sales price of the securities to be sold is in excess of $10,000.
  • The filing was made on August 14, 2023.
  • The SEC file number for this filing is 0001959173-23-003185.

Sources:

  • U.S. Securities and Exchange Commission (SEC) filing (Form 144) by Ginkgo Bioworks Holdings, Inc. on August 14, 2023 https://www.sec.gov/Archives/edgar/data/1830214/0001959173-23-003185-index.html.